Case report: Complete response of a bladder cancer patient with multiple hepatic and pelvic metastases treated by nab-paclitaxel combined with sintilimab

Article Oncology

Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03

Xinan Sheng et al.

Summary: The study demonstrates that Toripalimab has promising clinical activity in previously treated mUC patients with a manageable safety profile. PD-L1 expression and TMB were identified as independent biomarkers in this study.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Review Urology & Nephrology

The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma

Richard Cathomas et al.

Summary: The latest EAU guideline recommends platinum-based chemotherapy as the first-line standard therapy, with immunotherapy considered for PD-L1-positive patients who are ineligible for cisplatin, and maintenance immunotherapy recommended for those with nonprogressive disease.

EUROPEAN UROLOGY (2022)

添加到收藏夹

Article Oncology

Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma

Dingwei Ye et al.

Summary: Tislelizumab showed meaningful clinical benefits in patients with previously treated PD-L1-positive urothelial carcinoma, with a 24% objective response rate and a durable response rate of 68%. The most common adverse events were anemia and pyrexia.

CANCER SCIENCE (2021)

添加到收藏夹

Article Oncology

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles et al.

Summary: The study examined the outcomes of using pembrolizumab alone or combined with chemotherapy as first-line treatment for advanced urothelial carcinoma, and found that the addition of pembrolizumab to platinum-based chemotherapy did not significantly improve efficacy. Safety was assessed and the study concluded that this combination treatment should not be widely adopted for this type of cancer.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report

Jianzheng Wang et al.

Summary: In the treatment of urothelial carcinoma, immunotherapy shows advantages in second-line treatment. The domestic PD-1 inhibitor sintilimab may be an effective choice for treating advanced urothelial carcinoma.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation

Jian-zhou Cao et al.

Summary: This case report highlights the use of anlotinib combined with sintilimab in the treatment of metastatic urothelial bladder carcinoma (mUBC) patients with FGFR3 mutations, showing partial response and stable disease for over 11 months. The combination therapy was found to be safe and effective in improving the patient's quality of life.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology